Clinical Trial Update: Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007) [Phase 2]

View source ↗

Summary

The Phase 2 FXI Hemodialysis Study of MK-2060 in patients with end-stage renal disease on hemodialysis has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease

Drugs mentioned

• MK-2060

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: End-Stage Renal Disease, End-Stage Kidney Disease | Phase 2 | Status: COMPLETED | Results posted: 2025-11-17